clinical trial · NCT04975152
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute·phase1·active not recruiting·n = 36
Merkel Cell CarcinomaCutaneous Squamous Cell CarcinomaCemiplimab-Rwlc
brief summary
The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
started
Oct 22, 2021
primary completion
Mar 1, 2028
completion
Mar 1, 2028
last updated
Dec 5, 2025
official title
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol